Progresse Uses

Was this medicine useful for you?
sponsored

What is Progresse?

Progresse is used to help control partial seizures (convulsions) in the treatment of epilepsy. Progresse cannot cure epilepsy and will only work to control seizures for as long as you continue to take it.

Progresse is also used in adults to manage a condition called postherpetic neuralgia, which is pain that occurs after shingles.

Progresse works in the brain to prevent seizures and relieve pain for certain conditions in the nervous system. It is not used for routine pain caused by minor injuries or arthritis. Progresse is an anticonvulsant.

Progresse is available only with your doctor's prescription.

Once a medicine has been approved for marketing for a certain use, experience may show that it is also useful for other medical problems. Although this use is not included in product labeling, Progresse is used in certain patients with the following medical condition:

Progresse indications

sponsored

Oral

Epilepsy

Adult: Initially, 300 mg on the 1st day, 300 mg bid on the 2nd day and 300 mg tid on the 3rd day. Thereafter, may increase dose until effective antiepileptic control is achieved. Usual maintenance range: 0.9-3.6 g daily; daily dose to be taken in 3 equally divided doses and max dosing interval: 12 hr. Max: 4.8 g daily.

Child: ≥6 yr Initially, 10-15 mg/kg daily, titrated over a period of approx 3 days until effective antiepileptic control is achieved, usually w/in 25-35 mg/kg daily in 3 divided doses w/ max interval of 12 hr. Max: 50 mg/kg daily.

Renal impairment: Haemodialysis: Loading dose: 300-400 mg followed by 200-300 mg after each 4 hr of haemodialysis.

CrCl (ml/min)Dosage Recommendation
<15300 mg on alternate days to 300 mg daily.
15-29300 mg on alternate days to 600 mg daily.
30-49300-900 mg daily.
50-79600-1,800 mg daily.

Oral

Neuropathic pain

Adult: Initially, 300 mg on the 1st day, 300 mg bid on the 2nd day and 300 mg tid on the 3rd day; alternatively, 900 mg daily in 3 divided doses. Dose may increase in increments of 300 mg every 2-3 days. Max: 3,600 mg daily.

Renal impairment: Haemodialysis: Loading dose: 300-400 mg followed by 200-300 mg after each 4 hr of haemodialysis.

CrCl (ml/min)Dosage Recommendation
<15300 mg on alternate days to 300 mg daily.
15-29300 mg on alternate days to 600 mg daily.
30-49300-900 mg daily.
50-79600-1,800 mg daily.

Oral

Restless leg syndrome

Adult: As Progresse enacarbil: Modified-release preparation: Moderate to severe: 600 mg once daily at approx 5 pm.

Renal impairment: As Progresse enacarbil: Modified-release preparation:

Haemodialysis: Not recommended.

CrCl (ml/min)Dosage Recommendation
<15300 mg on alternate days.
15-29300 mg daily.
30-59Initially, 300 mg daily, increased to 600 mg daily, if needed.

Oral

Postherpetic neuralgia

Adult: As Progresse enacarbil: Modified-release preparation: Initially, 600 mg in the morning for 3 days, then increased to 600 mg bid.

Renal impairment: As Progresse enacarbil: Modified-release preparation:

Haemodialysis: 300 mg after each dialysis session, may increase to 600 mg if needed.

CrCl (ml/min)Dosage Recommendation
<15300 mg in the morning on alternate days, may increase to 300 mg daily in the morning.
15-29300 mg in the morning on days 1 and 3 followed by 300 mg daily in the morning, may increase to 300 mg bid.
30-59300 mg in the morning for the 1st 3 days followed by 300 mg bid, may increase to 600 mg bid.

How should I use Progresse?

Use Progresse capsules as directed by your doctor. Check the label on the medicine for exact dosing instructions.

Ask your health care provider any questions you may have about how to use Progresse capsules.

Uses of Progresse in details

sponsored

Progresse is used with other medications to prevent and control seizures. It is also used to relieve nerve pain following shingles (a painful rash due to herpes zoster infection) in adults. Progresse is known as an anticonvulsant or antiepileptic drug.

OTHER USES: This section contains uses of this drug that are not listed in the approved professional labeling for the drug but that may be prescribed by your health care professional. Use this drug for a condition that is listed in this section only if it has been so prescribed by your health care professional.

Progresse may also be used to treat other nerve pain conditions (such as diabetic neuropathy, peripheral neuropathy, trigeminal neuralgia) and restless legs syndrome.

How to use Progresse

Read the Medication Guide and, if available, the Patient Information Leaflet provided by your pharmacist before you start taking Progresse and each time you get a refill. If you have any questions, ask your doctor or pharmacist.

Take this medication by mouth with or without food as directed by your doctor. Dosage is based on your medical condition and response to treatment. For children, the dosage is also based on weight.

If you are taking the tablets and your doctor directs you to split the tablet in half, take the other half-tablet at your next scheduled dose. Discard half tablets if not used within several days of splitting them. If you are taking the capsules, swallow them whole with plenty of water.

It is very important to follow your doctor's dosing instructions exactly. During the first few days of treatment, your doctor may gradually increase your dose so your body can adjust to the medication. To minimize side effects, take the very first dose at bedtime.

Take this medication regularly to get the most benefit from it. This drug works best when the amount of medicine in your body is kept at a constant level. Therefore, take Progresse at evenly spaced intervals at the same time(s) each day. If you are taking this medication 3 times a day to control seizures, do not let more than 12 hours pass between doses because your seizures may increase.

Do not take this medication more often or increase your dose without consulting your doctor. Your condition will not improve any faster and the risk of serious side effects may increase.

Do not stop taking this medication without consulting your doctor. Some conditions may become worse when the drug is suddenly stopped. Your dose may need to be gradually decreased.

Antacids containing aluminum or magnesium may interfere with the absorption of this medication. Therefore, if you are also taking an antacid, it is best to take Progresse at least 2 hours after taking the antacid.

Different forms of Progresse (such as immediate-release, sustained-release, enacarbil sustained-release) are absorbed in the body differently. Do not switch from one form to the other without consulting your doctor.

Tell your doctor if your condition does not improve or if it worsens.

Progresse description

sponsored

Novo-Progresse (brand name Progresse) is a medication originally developed for the treatment of epilepsy. Presently, Progresse is widely used to relieve pain, especially neuropathic pain. Novo-Progresse is well tolerated in most patients, has a relatively mild side-effect profile, and passes through the body unmetabolized.

Progresse dosage

Progresse Dosage

Generic name: Progresse 300mg

Dosage form: tablet, film coated

The information at Drugs.com is not a substitute for medical advice. Always consult your doctor or pharmacist.

Postherpetic Neuralgia

Do not use Progresse interchangeably with other Progresse products.

Titrate Progresse to an 1800 mg dose taken orally once daily with the evening meal. Progresse tablets should be swallowed whole. Do not split, crush, or chew the tablets.

If Progresse dose is reduced, discontinued, or substituted with an alternative medication, this should be done gradually over a minimum of one week or longer (at the discretion of the prescriber).

In adults with postherpetic neuralgia, Progresse therapy should be initiated and titrated as follows:

Table 1: Progresse Recommended Titration Schedule
Day 1 Day 2 Days 3-6 Days 7-10 Days 11-14 Day 15
Daily Dose 300 mg 600 mg 900 mg 1200 mg 1500 mg 1800 mg

Patients with Renal Impairment

In patients with stable renal function, creatinine clearance (CCr) can be reasonably well estimated using the equation of Cockcroft and Gault:

For females CCr=(0.85)(140-age)(weight)/[(72)(SCr)]

For males CCr=(140-age)(weight)/[(72)(SCr)]

where age is in years, weight is in kilograms and SCr is serum creatinine in mg/dL.

The dose of Progresse should be adjusted in patients with reduced renal function, according to Table 2. Patients with reduced renal function must initiate Progresse at a daily dose of 300 mg. Progresse should be titrated following the schedule outlined in Table 1. Daily dosing in patients with reduced renal function must be individualized based on tolerability and desired clinical benefit.

Table 2: Progresse Dosage Based on Renal Function
Once-daily dosing
Creatinine Clearance (mL/min) Progresse Dose (once daily with evening meal)
≥ 60 1800 mg
30 - 60 600 mg to 1800 mg
< 30 Progresse should not be administered
patients receiving hemodialysis Progresse should not be administered

More about Progresse (Progresse)

Consumer resources

Professional resources

Related treatment guides

Progresse interactions

See also:
What other drugs will affect Progresse?

sponsored

There are spontaneous and literature case reports of respiratory depression and/or sedation associated with Progresse and opioid use. In some of these reports, the authors considered this a particular concern with the combination of Progresse and opioids, especially in elderly patients.

Morphine: In a study involving healthy volunteers (N=12) when a 60 mg controlled-release morphine capsule was administered 2 hours prior to a 600 mg Progresse capsule, mean Progresse AUC increased by 44% compared to Progresse administered without morphine. This was associated with an increased pain threshold (cold pressor test). The clinical significance of such changes has not been defined. Morphine pharmacokinetic parameter values were not affected by administration of Progresse 2 hours after morphine. The observed opioid-mediated side effects associated with morphine plus Progresse did not differ significantly from morphine plus placebo. The magnitude of interaction at other doses is not known.

No interaction between Progresse and phenobarbital, phenytoin, valproic acid or carbamazepine has been observed. Progresse steady-state pharmacokinetics are similar for healthy subjects and patients with epilepsy receiving these antiepileptic agents.

Co-administration of Progresse with oral contraceptives containing norethindrone and/or ethinyl estradiol does not influence the steady-state pharmacokinetics of either component.

Co-administration of Progresse with antacids containing aluminum and magnesium reduces Progresse bioavailability by about 20%. It is recommended that Progresse be taken about 2 hours following antacid administration.

Renal excretion of Progresse is unaltered by probenecid.

A slight decrease in renal excretion of Progresse observed when it is co-administered with cimetidine is not expected to be of clinical importance.

Laboratory Tests: False-positive readings were reported in the Ames N-Multistix SG dipstick test when Progresse was added to other anticonvulsant drugs. To determine urinary protein, the more specific sulfosalicylic acid precipitation procedure is recommended.

Progresse side effects

See also:
What are the possible side effects of Progresse?

Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

A total of 359 patients with neuropathic pain associated with postherpetic neuralgia have received Progresse at doses up to 1800 mg daily during placebo-controlled clinical studies. In clinical trials in patients with postherpetic neuralgia, 9.7% of the 359 patients treated with

Progresse and 6.9% of 364 patients treated with placebo discontinued prematurely due to adverse reactions. In the Progresse treatment group, the most common reason for discontinuation due to adverse reactions was dizziness. Of Progresse-treated patients who experienced adverse reactions in clinical studies, the majority of those adverse reactions were either “mild” or “moderate”.

Table 4 lists all adverse reactions, regardless of causality, occurring in at least 1% of patients with neuropathic pain associated with postherpetic neuralgia in the Progresse group for which the incidence was greater than in the placebo group.

Table 4: Treatment-Emergent Adverse Reaction Incidence in Controlled Trials in Neuropathic Pain Associated with Postherpetic Neuralgia (Events in at Least 1% of all Progresse-Treated Patients and More Frequent Than in the Placebo Group)

Body System - Preferred Term Progresse

N = 359

%

Placebo

N = 364

%

Ear and Labyrinth Disorders
Vertigo 1.4 0.5
Gastrointestinal Disorders
Diarrhea 3.3 2.7
Dry mouth 2.8 1.4
Constipation 1.4 0.3
Dyspepsia 1.4 0.8
General Disorders
Peripheral edema 3.9 0.3
Pain 1.1 0.5
Infections and Infestations
Nasopharyngitis 2.5 2.2
Urinary tract infection 1.7 0.5
Investigations
Weight increased 1.9 0.5
Musculoskeletal and Connective Tissue Disorders
Pain in extremity 1.9 0.5
Back pain 1.7 1.1
Nervous System Disorders
Dizziness 10.9 2.2
Somnolence 4.5 2.7
Headache 4.2 4.1
Lethargy 1.1 0.3

In addition to the adverse reactions reported in Table 4 above, the following adverse reactions with an uncertain relationship to Progresse were reported during the clinical development for the treatment of postherpetic neuralgia. Events in more than 1% of patients but equally or more frequently in the Progresse-treated patients than in the placebo group included blood pressure increase, confusional state, gastroenteritis viral, herpes zoster, hypertension, joint swelling, memory impairment, nausea, pneumonia, pyrexia, rash, seasonal allergy, and upper respiratory infection.

Postmarketing And Other Experience With Other Formulations Of Progresse

In addition to the adverse experiences reported during clinical testing of Progresse, the following adverse experiences have been reported in patients receiving other formulations of marketed Progresse. These adverse experiences have not been listed above and data are insufficient to support an estimate of their incidence or to establish causation. The listing is alphabetized: angioedema, blood glucose fluctuation, breast enlargement, elevated creatine kinase, elevated liver function tests, erythema multiforme, fever, hyponatremia, jaundice, movement disorder, Stevens-Johnson syndrome.

Adverse events following the abrupt discontinuation of Progresse immediate release have also been reported. The most frequently reported events were anxiety, insomnia, nausea, pain and sweating.

Progresse contraindications

See also:
What is the most important information I should know about Progresse?

You should not use this medication if you are allergic to Progresse.

Before taking Progresse, tell your doctor if you have kidney, liver, or heart disease.

You may have thoughts about suicide while taking Progresse. Your doctor will need to check you at regular visits. Do not miss any scheduled appointments.

Report any new or worsening symptoms to your doctor, such as: mood or behavior changes, anxiety, depression, or if you feel agitated, hostile, restless, hyperactive (mentally or physically), or have thoughts about suicide or hurting yourself.

Do not stop taking Progresse for seizures without first talking to your doctor, even if you feel fine. You may have increased seizures if you stop using Progresse suddenly. You may need to use less and less before you stop the medication completely.

Contact your doctor if your seizures get worse or you have them more often while taking Progresse.

Wear a medical alert tag or carry an ID card stating that you take Progresse. Any doctor, dentist, or emergency medical care provider who treats you should know that you take seizure medication.



Active ingredient matches for Progresse:

Gabapentin in Brazil.


List of Progresse substitutes (brand and generic names)

Sort by popularity
Unit description / dosage (Manufacturer)Price, USD
PROGABA-AM tab 10's (Mesmer (Icon))$ 1.42
Capsule; Oral; Gabapentin 100 mg
Capsule; Oral; Gabapentin 300 mg
Capsule; Oral; Gabapentin 400 mg
Capsules; Oral; Gabapentin 100 mg
Capsules; Oral; Gabapentin 300 mg
Capsules; Oral; Gabapentin 400 mg
Ran-gabapentin capsule 100 mg (Ranbaxy Pharmaceuticals Canada Inc. (Canada))
Ran-gabapentin capsule 300 mg (Ranbaxy Pharmaceuticals Canada Inc. (Canada))
Ran-gabapentin capsule 400 mg (Ranbaxy Pharmaceuticals Canada Inc. (Canada))
Capsule; Oral; Gabapentin 100 mg
Capsule; Oral; Gabapentin 300 mg
Capsule; Oral; Gabapentin 400 mg
Tablet; Oral; Gabapentin 600 mg
Tablet; Oral; Gabapentin 800 mg
Capsules; Oral; Gabapentin 100 mg
Capsules; Oral; Gabapentin 300 mg
Capsules; Oral; Gabapentin 400 mg
Tablets; Oral; Gabapentin 600 mg
Tablets; Oral; Gabapentin 800 mg
Ratio-gabapentin tablet 600 mg (Ratiopharm Inc Division Of Teva Canada Limited (Canada))
Ratio-gabapentin capsule 100 mg (Ratiopharm Inc Division Of Teva Canada Limited (Canada))
Ratio-gabapentin tablet 800 mg (Ratiopharm Inc Division Of Teva Canada Limited (Canada))
Ratio-gabapentin capsule 300 mg (Ratiopharm Inc Division Of Teva Canada Limited (Canada))
Ratio-gabapentin capsule 400 mg (Ratiopharm Inc Division Of Teva Canada Limited (Canada))
Reinin 100 mg x 100's (Medichem)$ 65.37
Reinin 300 mg x 100's (Medichem)$ 72.38
Reinin cap 100 mg 100's (Medichem)$ 0.74
Reinin cap 300 mg 100's (Medichem)$ 0.82
Reinin cap 600 mg 30's (Medichem)$ 1.51
Rejunate 300mg CAP / 10 (Molekule)$ 1.22
REJUNATE 300 MG CAPSULE 1 strip / 10 capsules each (Molekule)$ 1.16
REJUNATE cap 300 mg x 10's (Molekule)$ 0.84
Rejunate 300mg Capsule (Molekule)$ 0.12
Rejuron 300mg CAP / 10 (Molekule)$ 1.22
REJURON 300MG CAPSULE 1 strip / 10 capsules each (Molekule)$ 1.22
REJURON cap 300 mg x 10's (Molekule)$ 1.22
Rejuron 300mg Capsule (Molekule)$ 0.12
Remaltin 50 mg/1 mL x 120 mL
Remaltin 50 mg/1 mL x 240 mL
Remaltin 50 mg/1 mL x 470 mL
Remitat 300 mg x 3 Blister x 10 Tablet

References

  1. DailyMed. "GABAPENTIN: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
  2. PubChem. "gabapentin". https://pubchem.ncbi.nlm.nih.gov/com... (accessed September 17, 2018).
  3. DrugBank. "gabapentin". http://www.drugbank.ca/drugs/DB00996 (accessed September 17, 2018).

Reviews

The results of a survey conducted on ndrugs.com for Progresse are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Progresse. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.

User reports

Consumer reported useful

No survey data has been collected yet


Consumer reported price estimates

No survey data has been collected yet


Consumer reported time for results

No survey data has been collected yet


Consumer reported age

No survey data has been collected yet


Consumer reviews


There are no reviews yet. Be the first to write one!


Your name: 
Email: 
Spam protection:  < Type 19 here

Information checked by Dr. Sachin Kumar, MD Pharmacology

| Privacy Policy
This site does not supply any medicines. It contains prices for information purposes only.
© 2003 - 2024 ndrugs.com All Rights Reserved